Galas Kristin, Gleitsmann Moritz, Rey Julia, Solbach Christine, Witzel Isabell, Karn Thomas, Schmatloch Sabine, Schem Christian, Schneeweis Andreas, Sinn Bruno, Fehm Tanja, Denkert Carsten, Fasching Peter, Litmeyer Anne-Sophie, Marmé Frederik, Jank Paul, Müller Volkmar, Seiler Sabine, Stickeler Elmar, Ortmann Olaf, van Mackelenbergh Marion, Nekljudova Valentina, Holtschmidt Johannes, Loibl Sibylle
GBG c/o GBG Forschungs GmbH, Neu-Isenburg, Germany.
Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany.
NPJ Breast Cancer. 2025 May 14;11(1):43. doi: 10.1038/s41523-025-00758-3.
Breast cancer diagnosed during pregnancy (PrBC) is a rare occurrence but may become more prevalent as women nowadays tend to postpone childbearing until later in life. Further understanding of how pregnancy affects the tumor microenvironment (TME) is essential. We constructed Tissue Microarrays (TMA) of tumor specimens from 126 pregnant breast cancer (BC) patients and examined standard BC markers such as ER, PR, Ki67, HER2, tumor infiltrating lymphocytes (TILs), and immunomarkers HLA class I, HLA-G, PD-L1, TIGIT and Nectin-4. Subsequently, we compared our findings with those from a matched non-pregnant cohort of young BC patients. Pregnant BC patients were younger, had significantly higher proliferation rates and a higher expression of Nectin-4. Higher pregnancy related estrogen levels may boost proliferation und Nectin-4 overexpression, promoting BC progression. No further evidence supporting impaired maternal anti-tumor response in BC was observed in this study.
孕期诊断出的乳腺癌（PrBC）较为罕见，但随着如今女性倾向于将生育推迟到更晚的年龄，其发病率可能会更高。进一步了解妊娠如何影响肿瘤微环境（TME）至关重要。我们构建了126例妊娠乳腺癌（BC）患者肿瘤标本的组织芯片（TMA），并检测了标准的BC标志物，如雌激素受体（ER）、孕激素受体（PR）、Ki67、人表皮生长因子受体2（HER2）、肿瘤浸润淋巴细胞（TILs）以及免疫标志物人类白细胞抗原I类分子（HLA class I）、HLA-G、程序性死亡受体配体1（PD-L1）、T细胞免疫球蛋白和粘蛋白结构域分子3（TIGIT）以及nectin-4。随后，我们将研究结果与一组匹配的非妊娠年轻BC患者队列的结果进行了比较。妊娠BC患者更年轻，增殖率显著更高，且nectin-4表达更高。较高的与妊娠相关的雌激素水平可能会促进增殖以及nectin-4的过表达，从而促进BC进展。在本研究中未观察到支持BC患者母体抗肿瘤反应受损的进一步证据。
